Literature DB >> 28786416

Breast cancer: T-DM1 - an important agent in the history of breast cancer management.

Otto Metzger-Filho1, Eric P Winer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786416     DOI： 10.1038/nrclinonc.2017.123

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  13 in total

1.  Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

Authors:  José Baselga; Gail D Lewis Phillips; Sunil Verma; Jungsil Ro; Jens Huober; Alice E Guardino; Meghna K Samant; Steve Olsen; Sanne L de Haas; Mark D Pegram
Journal:  Clin Cancer Res       Date:  2016-02-26       Impact factor: 12.531

2.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

3.  Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

Authors:  Ian E Krop; Sung-Bae Kim; Antonio Gonzalez Martin; Patricia M LoRusso; Jean-Marc Ferrero; Tanja Badovinac-Crnjevic; Silke Hoersch; Melanie Smitt; Hans Wildiers
Journal:  Lancet Oncol       Date:  2017-05-16       Impact factor: 41.316

4.  Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Authors:  Véronique Diéras; David Miles; Sunil Verma; Mark Pegram; Manfred Welslau; José Baselga; Ian E Krop; Kim Blackwell; Silke Hoersch; Jin Xu; Marjorie Green; Luca Gianni
Journal:  Lancet Oncol       Date:  2017-05-16       Impact factor: 41.316

5.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Authors:  Ian E Krop; Sung-Bae Kim; Antonio González-Martín; Patricia M LoRusso; Jean-Marc Ferrero; Melanie Smitt; Ron Yu; Abraham C F Leung; Hans Wildiers
Journal:  Lancet Oncol       Date:  2014-05-02       Impact factor: 41.316

6.  Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.

Authors:  Frank Loganzo; Xingzhi Tan; Matthew Sung; Guixian Jin; Jeremy S Myers; Eugene Melamud; Fang Wang; Veronica Diesl; Maximillian T Follettie; Sylvia Musto; My-Hanh Lam; William Hu; Manoj B Charati; Kiran Khandke; Kenny Sung Kyoo Kim; Mike Cinque; Judy Lucas; Edmund Graziani; Andreas Maderna; Christopher J O'Donnell; Kim T Arndt; Hans-Peter Gerber
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

7.  Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.

Authors:  Sung-Bae Kim; Hans Wildiers; Ian E Krop; Melanie Smitt; Ron Yu; Sanne Lysbet de Haas; Antonio Gonzalez-Martin
Journal:  Int J Cancer       Date:  2016-07-26       Impact factor: 7.396

8.  Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

Authors:  Philipp Müller; Matthias Kreuzaler; Tarik Khan; Daniela S Thommen; Kea Martin; Katharina Glatz; Spasenija Savic; Nadia Harbeck; Ulrike Nitz; Oleg Gluz; Michael von Bergwelt-Baildon; Hans Kreipe; Sai Reddy; Matthias Christgen; Alfred Zippelius
Journal:  Sci Transl Med       Date:  2015-11-25       Impact factor: 17.956

9.  Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Authors:  Ian Krop; Eric P Winer
Journal:  Clin Cancer Res       Date:  2013-10-17       Impact factor: 12.531

10.  Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

Authors:  I E Krop; N U Lin; K Blackwell; E Guardino; J Huober; M Lu; D Miles; M Samant; M Welslau; V Diéras
Journal:  Ann Oncol       Date:  2014-10-29       Impact factor: 32.976
View more
  4 in total

Review 1.  Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.

Authors:  Luis Manso; Alfonso Sanchez-Muñoz; Isabel Calvo; Yann Izarzugaza; Jessica Plata; Cesar Rodriguez
Journal:  Breast Care (Basel)       Date:  2018-07-13       Impact factor: 2.860

2.  Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.

Authors:  Otto Metzger Filho; Giuseppe Viale; Shayna Stein; Lorenzo Trippa; Denise A Yardley; Ingrid A Mayer; Vandana G Abramson; Carlos L Arteaga; Laura M Spring; Adrienne G Waks; Eileen Wrabel; Michelle K DeMeo; Aditya Bardia; Patrizia Dell'Orto; Leila Russo; Tari A King; Kornelia Polyak; Franziska Michor; Eric P Winer; Ian E Krop
Journal:  Cancer Discov       Date:  2021-05-03       Impact factor: 39.397

3.  Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.

Authors:  Baoying Shi; Min Wu; Zhaohui Li; Zhangming Xie; Xiaoyue Wei; Jiansheng Fan; Yingchun Xu; Ding Ding; Sajid Hamid Akash; Shuqing Chen; Sheldon Cao
Journal:  Cancer Med       Date:  2019-03-07       Impact factor: 4.452

4.  Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.

Authors:  Wei-Ying Kuo; Hung-Ju Hsu; Chun-Yi Wu; Hong-Sen Chen; Yu-Chi Chou; Yueh-Liang Tsou; Hung-Pin Peng; Jhih-Wei Jian; Chung-Ming Yu; Yi-Kai Chiu; Ing-Chien Chen; Chao-Ping Tung; Michael Hsiao; Chia-Lung Lin; Yong Alison Wang; Andrew H-J Wang; An-Suei Yang
Journal:  MAbs       Date:  2018-11-08       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.